BioSpace News Archive

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.

Oncolytics Biotech ® Inc. today announced the poster presentation of interim results from the Phase 1/2 GOBLET study evaluating a combination treatment of pelareorep in patients with third-line (3L) metastatic colorectal cancer (CRC) regardless of microsatellite instability status at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain.

Ayana Bio today announced the launch of its Plant Cell Advantage™ (PCA™) ingredient portfolio, including Dog Rose PCA™, Hedge Nettle PCA™, and Sage PCA™ as the latest additions in its offering of plant cell-cultivated health and wellness ingredients.

Kazia Therapeutics Limited announces that selected clinical data from the company’s ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at the European Society of Medical Oncology Congress 2023 (ESMO 2023).

Oncolytics Biotech ® Inc. today announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain.

Viking Therapeutics, Inc. today announced the completion of patient enrollment in its Phase 2 clinical trial of VK2735, the company’s wholly-owned dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Bicara Therapeutics today announced the presentation of updated, positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101, a first-in-class bifunctional EGFR/TGF-β antibody, at the European Society for Medical Oncology (ESMO) Congress 2023.

Precision BioSciences, Inc. today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.

Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled preclinical data demonstrating the efficacy of Circle’s oral Cyclin A/B inhibitor macrocycles in patient-derived breast cancer tumor models.

Aviceda Therapeutics announced today that enrollment in part 1 of the SIGLEC Phase 2/3 U.S. clinical trial is complete and the Company is preparing to shortly initiate part 2.